Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| EXAS | EXACT SCIENCES CORP | 2025-10-16 23:27:31 | 60.9 | -0.39 | -0.64 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXAS | 0001124140 | EXACT SCIENCES CORP | US30063P1057 | 549300VM3X1FYD4N9Z14 | 204782291 | Nasdaq | 8071 | Services-Medical Laboratories | 1231 | DE | 5505 ENDEAVOR LANE | MADISON | WI | 53719 | UNITED STATES | US | 608-284-5700 | 5505 ENDEAVOR LANE, MADISON, WI, 53719 | 5505 ENDEAVOR LANE, MADISON, WI, 53719 | EXACT CORP | — | 1995 | Kevin Conroy | 6,500 | http://exactsciences.com | 7,726,320,579 | 189,220,577 | 189,319,110 | Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer. Since then Exact Sciences has grown its product portfolio to encompass other screening and precision oncological tests for other types of cancer. | 2025-10-10 19:48:03 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 7,726,320,579 | -9,070,030,559 | -54.0 | 185,755,406 | 4,224,439 | 2.3271 |
| 2023 | 16,796,351,138 | 9,891,286,107 | 143.2468 | 181,530,967 | 3,313,825 | 1.8594 |
| 2021 | 6,905,065,031 | -5,996,087,023 | -46.4771 | 178,217,142 | 9,123,980 | 5.3958 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Elliott | Chief Financial Officer, Executive Vice President | 2024 | 392,176 | 0 | 273,173 | 0 | 2,556,092 | 3,221,441 |
| Jacob Orville | Executive Vice President | 2024 | 618,000 | 0 | 3,581,298 | 202,812 | 31,082 | 4,433,192 |
| Kevin Conroy | Chief Executive Officer, Chairman, President | 2024 | 1,083,368 | 0 | 13,496,138 | 712,329 | 247,543 | 15,539,378 |
| Aaron Bloomer | Chief Financial Officer, Executive Vice President | 2024 | 431,868 | 600,000 | 6,002,837 | 136,662 | 15,421 | 7,186,788 |
| Brian Baranick | Executive Vice President | 2024 | 600,400 | 0 | 3,581,298 | 196,980 | 20,990 | 4,399,668 |
| Fiscal Year | Employee Count |
|---|---|
| 2019 | 4,110 |
| 2012 | 87 |
| 2011 | 61 |
| Fiscal Year | 2024 | 2023 | 2021 |
|---|---|---|---|
| Revenue | 2,758,867,000 | 2,499,766,000 | 1,767,087,000 |
| Cost Of Revenue | 840,150,000 | 654,248,000 | 458,757,000 |
| Gross Profit | 1,918,717,000 | — | 333,538,000 |
| Research And Development Expenses | 431,210,000 | 425,882,000 | 385,646,000 |
| General And Administrative Expenses | 781,825,000 | 893,204,000 | 801,262,000 |
| Operating Expenses | 2,976,620,000 | 2,793,205,000 | 2,622,765,000 |
| Operating Income | -1,048,703,000 | -215,012,000 | -855,678,000 |
| Net Income | -1,028,857,000 | -204,149,000 | -595,625,000 |
| Earnings Per Share Basic | -5.59 | -1.13 | -3.48 |
| Earnings Per Share Diluted | -5.59 | -1.13 | -3.48 |
| Weighted Average Shares Outstanding Basic | 184,197,000 | 180,144,000 | 171,348,000 |
| Weighted Average Shares Outstanding Diluted | 184,197,000 | 180,144,000 | 171,348,000 |
| Fiscal Year | 2024 | 2023 | 2021 |
|---|---|---|---|
| Cash And Cash Equivalents | 600,889,000 | 605,378,000 | 315,471,000 |
| Marketable Securities Current | 437,137,000 | 172,266,000 | 715,005,000 |
| Accounts Receivable | 248,968,000 | 203,623,000 | 216,645,000 |
| Inventories | 162,383,000 | 127,475,000 | 104,994,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 1,571,423,000 | 1,194,369,000 | 1,426,237,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 693,673,000 | 698,354,000 | 580,248,000 |
| Other Assets Non Current | 169,722,000 | 177,387,000 | 74,591,000 |
| Total Assets Non Current | 4,356,716,000 | 5,276,965,000 | 5,258,647,000 |
| Total Assets | 5,928,139,000 | 6,471,334,000 | 6,684,884,000 |
| Accounts Payable | 89,572,000 | 78,816,000 | 67,829,000 |
| Deferred Revenue | — | — | 1,000,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 37,765,000 | 14,823,000 | 30,973,000 |
| Total Liabilities Current | 732,187,000 | 514,701,000 | 517,068,000 |
| Long Term Debt | — | 50,000,000 | — |
| Other Liabilities Non Current | 315,503,000 | 335,982,000 | 417,782,000 |
| Total Liabilities Non Current | 2,793,703,000 | 2,811,328,000 | 2,780,180,000 |
| Total Liabilities | 3,525,890,000 | 3,326,029,000 | 3,297,248,000 |
| Common Stock | 1,857,000 | 1,815,000 | 1,738,000 |
| Retained Earnings | -4,498,032,000 | -3,469,175,000 | -2,641,520,000 |
| Accumulated Other Comprehensive Income | -944,000 | 1,428,000 | -1,443,000 |
| Total Shareholders Equity | 2,402,249,000 | 3,145,305,000 | 3,387,636,000 |
| Fiscal Year | 2024 | 2023 | 2021 |
|---|---|---|---|
| Depreciation And Amortization | 119,701,000 | — | 85,300,000 |
| Share Based Compensation Expense | 214,885,000 | 231,312,000 | 253,063,000 |
| Other Non Cash Income Expense | 519,000 | — | -1,055,000 |
| Change In Accounts Receivable | 46,259,000 | 43,416,000 | -25,150,000 |
| Change In Inventories | 34,911,000 | 7,690,000 | 9,221,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 2,323,000 | 11,618,000 | — |
| Change In Accounts Payable | 43,538,000 | 82,750,000 | 169,800,000 |
| Change In Other Liabilities | 9,726,000 | 6,333,000 | 57,935,000 |
| Cash From Operating Activities | 210,536,000 | 156,119,000 | -102,236,000 |
| Purchases Of Marketable Securities | 465,031,000 | 139,854,000 | 1,164,050,000 |
| Sales Of Marketable Securities | 205,821,000 | 363,156,000 | 794,322,000 |
| Acquisition Of Property Plant And Equipment | 135,989,000 | 124,190,000 | 135,766,000 |
| Acquisition Of Business | 0 | 52,413,000 | 499,730,000 |
| Other Investing Activities | 225,000 | -250,000 | 744,000 |
| Cash From Investing Activities | -442,155,000 | 49,679,000 | -1,082,085,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 31,227,000 | 28,344,000 | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | -17,754,000 | -9,751,000 | -5,286,000 |
| Cash From Financing Activities | 231,874,000 | 159,766,000 | 8,472,000 |
| Change In Cash | -3,039,000 | 366,885,000 | -1,175,826,000 |
| Cash At End Of Period | 600,889,000 | 605,378,000 | 315,471,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 27,839,000 | 18,776,000 | 10,735,000 |
| Fiscal Year | 2024 | 2023 | 2021 |
|---|---|---|---|
| Earnings Per Share | -5.59 | -1.13 | -3.48 |
| Price To Earnings Ratio | -10.0519 | -65.469 | -22.3649 |
| Earnings Growth Rate | 394.6903 | -67.5287 | 24.7312 |
| Price Earnings To Growth Ratio | -0.0255 | 0.9695 | -0.9043 |
| Book Value Per Share | 13.0417 | 17.4599 | 19.7705 |
| Price To Book Ratio | 4.3085 | 4.2371 | 3.9367 |
| Ebitda | -886,842,000 | — | -491,719,000 |
| Enterprise Value | — | 12,771,675,120 | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | 0.0159 | — |
| Capital Expenditures | 115,020,000 | — | 214,865,000 |
| Free Cash Flow | 95,516,000 | — | -317,101,000 |
| Return On Equity | -0.4283 | -0.0649 | -0.1758 |
| One Year Beta | 0.4312 | 1.7134 | 1.0383 |
| Three Year Beta | 1.5114 | 1.6075 | 1.1313 |
| Five Year Beta | 1.2482 | 1.3396 | 1.2371 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Doyle James Edward | Director | 2025-10-09 | 2,000 | D | 57,962 |
| Herriott James | SVP, General Counsel & Sec | 2025-10-09 | 1,500 | D | 14,085 |
| Doyle James Edward | Director | 2025-08-13 | 1,485 | D | 59,962 |
| Baranick Brian | EVP, GM, Precision Oncology | 2025-08-05 | 5,350 | A | 27,943 |
| Baranick Brian | EVP, GM, Precision Oncology | 2025-08-05 | 2,717 | D | 25,226 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Josh Gottheimer | 2024-06-08 | NJ05 | Sale | 2024-05-10 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2024-03-07 | NJ05 | Sale (Partial) | 2024-02-01 | Joint | $1,001 - $15,000 |
| Kevin Hern | 2024-02-11 | OK01 | Sale | 2024-01-02 | Child | $1,001 - $15,000 |
| Josh Gottheimer | 2023-12-08 | NJ05 | Sale (Partial) | 2023-11-13 | Joint | $1,001 - $15,000 |
| Josh Gottheimer | 2023-11-11 | NJ05 | Purchase | 2023-10-16 | Joint | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Capital Advisors, Ltd. LLC | 2025-09-30 | 1,000 | 21 | 47.619 |
| NVWM, LLC | 2025-09-30 | 71,998 | 1,316 | 54.7097 |
| City State Bank | 2025-09-30 | 5,471 | 100 | 54.71 |
| Blue Trust, Inc. | 2025-09-30 | 84,691 | 1,548 | 54.7099 |
| CWM, LLC | 2025-09-30 | 3,882,000 | 70,953 | 54.7123 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 826 | 38,780.7 | 0.0159 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 35,721 | 1,677,100.95 | 0.0708 |
| BNY Mellon ETF Trust | 2025-07-31 | BNY Mellon US Mid Cap Core Equity ETF | BKMC | 28,472 | 1,336,760.4 | 0.2396 |
| PACE SELECT ADVISORS TRUST | 2025-07-31 | Class P2 | PAPTX | -4,376 | -205,453.2 | -0.0739 |
| PACE SELECT ADVISORS TRUST | 2025-07-31 | Class P | PASPX | -4,376 | -205,453.2 | -0.0739 |